Fisher & Paykel Healthcare is a long-term play

Fisher & Paykel Healthcare is a long-term play
Chief executive Lewis Gradon (Image: Fisher & Paykel Healthcare)
Rebecca Howard
Fisher & Paykel Healthcare will benefit from the fact that its nasal high-flow therapy machine became the frontline choice for covid-19, but it won’t happen overnight. “The only real thing that covid-19 changed is that customers have a lot of the hardware,” said chief executive Lewis Gradon. Revenue in the year to March 31, 2019, was just over $1 billion. By the 2021 financial year, it had jumped to nearly $2b as the company moved swiftly to supply hospitals around the world with nasal high-flow therapy mach...

More Markets

Convention centre subbies say fire not their fault
Property

Convention centre subbies say fire not their fault

Millions at stake in the Fletcher v subbies trial.

One big, beautiful breather for Infratil’s US exposure
Markets

One big, beautiful breather for Infratil’s US exposure

Analysts say Trump’s policy is ‘more positive’ than Infratil had picked.

Boyes ups Infratil stake; resignations aplenty on NZX
Markets Market Close

Boyes ups Infratil stake; resignations aplenty on NZX

The benchmark index traded flat.

Gregor Thompson 07 Jul 2025